Real-World Experience With Maribavir for Treatment of Cytomegalovirus Infection in High-Risk Solid Organ Transplant Recipients.
Open Forum Infect Dis
; 11(7): ofae335, 2024 Jul.
Article
in En
| MEDLINE
| ID: mdl-38957689
ABSTRACT
We evaluated use of maribavir (MBV) for treatment of 15 episodes of refractory/resistant cytomegalovirus infection in 13 solid organ transplant recipients. Treatment failure due to treatment-emergent MBV resistance or early virological recurrence after MBV discontinuation occurred in 7 (47%) episodes. Sustained viral clearance was achieved in 6 (40%) episodes.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Language:
En
Journal:
Open Forum Infect Dis
Year:
2024
Document type:
Article
Affiliation country:
Country of publication: